University of Toronto

Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials (2019) Zinman B, Verma S, Bain SC, Honore JB, Mann J, Nauck MA, Pratley R, et al. Conference contribution Pathogenic WDFY3 variants cause neurodevelopmental disorders and opposing effects on brain size (2019) Le Duc D, Giulivi C, Hiatt SM, Napoli E, Panoutsopoulos A, Harlan De Crescenzo A, Kotzaeridou U, et al. Journal article Multicenter, International Assessment of the Eighth Edition of the American Joint Committee on Cancer Cancer Staging Manual for Conjunctival Melanoma (2019) Jain P, Finger PT, Damato B, Coupland SE, Heimann H, Kenawy N, Brouwer NJ, et al. Journal article Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology (2019) Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, et al. Journal article De novo missense variants in RHOBTB2 cause a developmental and epileptic encephalopathy in humans, and altered levels cause neurological defects in Drosophila (2019) Straub J, Konrad E, Grüner J, Toutain A, Bok LA, Cho MT, Crawford HP, et al. Conference contribution Exploring the complex etiology of oncogenic fusions in childhood cancer (2019) Anderson ND, De Borja R, Young MD, Fuligni F, Rosic A, Roberts ND, Pillay N, et al. Conference contribution ICAR: endoscopic skull-base surgery (2019) Wang EW, Zanation AM, Gardner PA, Schwartz TH, Eloy JA, Adappa ND, Bettag M, et al. Journal article EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution